Avidity Biosciences, Inc. (RNAM)
NASDAQ: RNAM · Real-Time Price · USD
72.82
+0.02 (0.03%)
At close: Feb 26, 2026
Avidity Biosciences Employees
Avidity Biosciences had 511 employees as of December 31, 2025. The number of employees increased by 120 or 30.69% compared to the previous year.
Employees
511
Change (1Y)
120
Growth (1Y)
30.69%
Revenue / Employee
$36,703
Profits / Employee
-$1,339,787
Market Cap
11.30B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 511 | 120 | 30.69% |
| Dec 31, 2024 | 391 | 138 | 54.55% |
| Dec 31, 2023 | 253 | 67 | 36.02% |
| Dec 31, 2022 | 186 | 61 | 48.80% |
| Dec 31, 2021 | 125 | 54 | 76.06% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,040 |
| Jazz Pharmaceuticals | 2,890 |
| Exelixis | 1,077 |
| Ionis Pharmaceuticals | 1,069 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 730 |
| ImmunityBio | 673 |
| Avidity Biosciences | 391 |
RNAM News
- 6 hours ago - Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - PRNewsWire
- 3 days ago - Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders - PRNewsWire
- 8 days ago - The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - PRNewsWire
- 24 days ago - Avidity Biosciences Announces Expected Record Date for Spin-Off - PRNewsWire
- 4 weeks ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 4 weeks ago - Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development - Accesswire
- 6 weeks ago - Pharma sector doubles down on AI amid hopes of slashing costs, timelines - Reuters
- 2 months ago - Top 2 Health Care Stocks That May Keep You Up At Night In December - Benzinga